Physician profile
Mark A Cepela
NPI 1730181009
$2,737.73
in general payments reported to CMS, 2019-2025
13 companies · $351 in 2025
The $351 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $156 · 2021: $260 · 2022: $303 · 2023: $310 · 2024: $745 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,406.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $542.54 | 2019-2023 | Tepezza |
| Merz North America, INC. | $388.78 | 2019-2022 | |
| Biotissue Holdings INC. | $373.34 | 2022-2024 | |
| Abbvie INC. | $319.44 | 2022-2025 | Botox |
| Amgen INC. | $317.01 | 2024 | Tepezza |
| Halozyme INC | $174.31 | 2019-2025 | Hylenex Recombinant |
| Harrow Eye, LLC | $149.80 | 2025 | Vevye |
| Allergan, INC. | $125.00 | 2019 | |
| Galderma Laboratories, L.P. | $122.44 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $98.84 | 2019 | |
| Ocular Therapeutix, INC. | $84.29 | 2024 | Dextenza |
| Astellas Pharma US INC | $23.31 | 2023 | |
| Glaukos Corporation | $18.63 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Cepela listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.